Header background image

Welcome to your expert
Cancer Associated
Thrombosis resource

eduCATe is an educational scientific resource
for healthcare professionals focusing on
Cancer Associated Thrombosis (CAT), to support
management of this highly prevalent condition.

CAT is the most common cause of chemotherapy mortality
and requires similar emphasis to neutropenic sepsis in people with cancer.

Noble S. Patient Preference and Adherence 2015; 9: 337‑345.

COVID-19: REWRITING THE RULES
IN THROMBOSIS

CLICK HERE TO READ MORE

Your CAT Expert Panel:

Expert Panel
introduction

Introduction
arrow icon

We are delighted to welcome you to eduCATe, the new CAThrombosis.com website. As the Expert Panel, our objective is to create a central information hub on Cancer Associated Thrombosis to support decision making by healthcare professionals involved in treating people with cancer.

Alongside the latest clinical information and data you will now find new interactive content such as our case studies section where you can contribute and share your experience. Over the coming months we will continue to drive new content, ensuring the site is regularly updated with current information in a variety of formats.

We hope you enjoy the updated website and encourage you to register to access content and to benefit from the newer interactive sections, such as the case study presentations.

Anthony Maraveyas

Hull York Medical School

Anthony Maraveyas is Professor of Cancer Medicine at Hull York Medical School which he joined as part of the founding team in 1999.

He graduated from Athens Medical School in 1983 and completed internal medicine training in 1990. In 1995 he was awarded PhD from the University of London on monoclonal antibodies in Head and Neck Cancer. His laboratory interests include the molecular role of Tissue Factor (TF) in the propagation of cancer. Amongst his clinical research activity he has been national chief investigator for a number of studies in cancer associated thrombosis. He has published widely in this field with particular focus on the thromboprophylaxis of the ambulant cancer patient and the management of incidental pulmonary embolism in cancer patients. He treats pancreaticobiliary, kidney cancer and melanoma.

Mike Laffan

Imperial College, London

Mike Laffan is Professor of Haemostasis and Thrombosis in the Department of Haematology at Imperial College, London, UK, and Director of the Hammersmith Hospital Haemophilia Centre, London, UK. He trained in medicine at the University of Oxford, UK, and in Haematology at the Hammersmith and Royal Free Hospitals in London. His principal research interests include the structure-function relationship of von Willebrand factor, in particular the role of glycosylation, mechanisms and regulation of thrombin generation and application of genomics to haemostasis.

He is chair of the UKHCDO Working Party on von Willebrand disease and recently completed six years as chair the British Society for Haematology Task Force on Haemostasis and Thrombosis. He led the UKHCDO Clinical Studies Group which recently published a James Lind Alliance partnership paper on priorities in bleeding disorders research. He is a member of the ASH VWD clinical guideline writing group. He has been co-PI of the NIHR-BRIDGE pilot study for the 100k genomes project. He is an editor of Practical Haematology (now in its 12th edition) and of Postgraduate Haematology.

Kieron Power

Singleton Hospital, Swansea Bay University Health Board, UK

Kieron Power is lead pharmacist for thrombosis and anticoagulation at Singleton Hospital. Having graduated from the University of Portsmouth in 2009, Kieron undertook his basic training at Singleton hospital. Initially specialising in care of older persons, his role has since changed to focus on thrombosis and anticoagulation. As lead of the acute ambulatory VTE service, he has developed the service to become the primary ambulatory hub for management of VTE in the health board. As part of this work, Kieron has developed a cancer specific pathway that has been commended both locally and nationally. In the last 12 months the pharmacy-led service has won awards at the Welsh Pharmacy Awards and recognised at the Anticoagulant Achievement Awards.

Kieron also is secretary and clinical lead for the health board Thrombosis and Anticoagulation committee and sits on the All Wales VTE and hospital acquired thrombosis (HAT) committees. Kieron’s works closely with Swansea University and the Welsh Centre for Emergency Medicine Research. His primary research interests have been around patient experience in dealing with cancer associated thrombosis.

Join ‘Let’s talk clots’, the Thrombosis UK virtual conference in support of World Thrombosis Day.
1017 October 2020

CLICK HERE TO FIND OUT MORE

 

Up to 1 in 5 people with cancer will experience a clot
Lee AY. Br J Haematol 2005; 128: 291-302.
CLICK HERE TO FIND OUT MORE

Case studies

Here we invite submission of case studies demonstrating management approaches to CAT

CLICK HERE TO FIND OUT MORE

Recent research

Review the PubMed resource to find the latest data on CAT.

CLICK HERE TO FIND OUT MORE

Annual incidence of VTE in people with cancer receiving chemotherapy

10% to 21% depending on the type of drug(s) administered
Lyman GH, et al. Oncologist 2013; 18: 1321-9.
CLICK HERE TO FIND OUT MORE

Coming soon: E-learning

Test your knowledge of CAT with the e-learning module. CPD accredited.

click here to find out more